References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
- Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England J Med. 2005;352:987–996.
- Messali A, Villacorta R, Hay JW. A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics. 2014;32:1201–1212.
- Raizer JJ, Fitzner KA, Jacobs DI, et al. Economics of malignant gliomas: a critical review. J Oncol Pract. 2014;11:e59–e65.
- Silverstein MD, Cascino TL, Harmsen WS. High-grade astrocytomas: resource use, clinical outcomes, and cost of care. Mayo Clin Proc. 1996;71(10):936-944.
- Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22:3524–3530.
- Wasserfallen J-B, Ostermann S, Leyvraz S, et al. Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death. Neuro Oncol. 2005;7:189–195.
- Patterson H Nobody can afford a brain tumor. The financial impacts of brain tumors on patients and families: a summary of findings. National Brain Tumor Foundation; 2007.
- Blomqvist P, Lycke J, Strang P, et al. Brain tumours in Sweden 1996: care and costs. J Neurology Neurosurg Psychiatry. 2000;69:792–798.
- Kaplan RS. Improving value with TDABC. Healthc Financial Manag. 2014;68:76–84.
- Donovan CJ, Hopkins M, Kimmel BM, et al. How Cleveland clinic used TDABC to improve value. Healthc Financial Manag. 2014;68:84–89.
- Porter ME, Teisberg EO. Redefining health care: creating value-based competition on results. Harvard Business Press; 2006.
- Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation. 1992;85:1960–1968.
- Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New England J Med. 2005;352:997–1003.
- Roa W, Brasher P, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583–1588.
- Kovic B, Xie F. Economic evaluation of bevacizumab for the first-line treatment of newly diagnosed glioblastoma multiforme. J Clin Oncol. 2015;33:2296–2302.
- Bernard-Arnoux F, Lamure M, Ducray F, et al. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2016;18:1129–1136.
- Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34:2925–2934.
- Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26(8):1547-1573.
- Schrag D. Value frameworks in oncology. ASCO Annual Meeting. Plenary Lecture, Chicago, IL; 2016 Jun 5.
- Mariotto AB, Robin Yabroff K, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. JNCI J Natl Cancer Inst. 2011;103:117–128.